VIVEbiotech Highlights Lentiviral Vector Manufacturing in CIRM Webinar
VIVEbiotech has showcased its expertise in lentiviral vector development and manufacturing in a recent webinar hosted in its capacity as a CIRM Industry Resource Partner of the California Institute for Regenerative Medicine (CIRM).
The session, organized in collaboration with the California Institute for Regenerative Medicine (CIRM), highlighted VIVEbiotech’s end-to-end capabilities, the versatility of its platform, and its expertise in both ex vivo and in vivo gene therapy applications, with a growing focus on the latter, reinforcing its position as a specialized CDMO in lentiviral vector manufacturing.
The webinar featured Natalia Elizalde, PhD, Chief Business Development Officer, and Marie Fertin, Chief Custom Solutions & Process Development Officer, who presented VIVEbiotech’s approach to supporting lentiviral vector programs across all development stages.
During the session, VIVEbiotech provided a comprehensive overview of its proprietary lentiviral vector manufacturing platform, designed to address a wide range of project requirements—from early-stage development through to GMP manufacturing for clinical and commercial use. The company emphasized its ability to deliver scalable, flexible, and customized solutions tailored to each partner’s specific needs.
A key focus of the webinar was VIVEbiotech’s expanding expertise in in vivo applications. The speakers covered critical aspects of lentiviral vector development, including vector design, scalability, process development, and analytical requirements. They also addressed the additional complexities associated with in vivo gene therapy and outlined the strategies implemented to effectively manage these challenges.
The webinar included several case studies demonstrating how VIVEbiotech supports the efficient progression of lentiviral vector programs. These examples showed improvements in key performance indicators such as vector titer, purity, and cost-efficiency, as well as the company’s capability to overcome specific development and manufacturing challenges.
In addition, VIVEbiotech presented its approach to project design, based on a structured yet flexible model that enables seamless progression from early development stages through non-GMP and GMP manufacturing. This approach relies on close collaboration with partners and a strong focus on adapting to each program’s specific requirements.
The session also introduced EvoLVcell, VIVEbiotech’s stable lentiviral vector producer cell line technology, designed to enhance manufacturing consistency, reduce variability, and improve overall process efficiency by eliminating the need for transient transfection.
The webinar concluded with a final Q&A session addressing key challenges in lentiviral vector manufacturing, including scalability, process optimization, timelines, and regulatory considerations for gene therapy development.
This initiative reflects VIVEbiotech’s ongoing commitment to advancing innovative cell and gene therapies by delivering robust, scalable, and high-quality lentiviral vector manufacturing solutions.
Many thanks to CIRM for this great opportunity and to our speakers, Natalia and Marie, for their valuable contributions.
🎥 The full webinar is available here: https://www.youtube.com/watch?v=wONduQBGjnU&t=2562s